| Similar Articles |
|---|
 |
The Motley Fool
October 26, 2004
Charly Travers |
Sepracor's Tough Road to Profits Will insomnia drug Estorra take the company to the promised land?   |
The Motley Fool
May 2, 2008
Brian Orelli |
Sepracor Diversifies to Sleep Better With its two top drugs in decline, diversification was the only answer for Sepracor. |
The Motley Fool
July 21, 2006
Brian Lawler |
Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady. |
The Motley Fool
August 13, 2004
Charly Travers |
Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition. |
The Motley Fool
October 31, 2007
Brian Orelli |
A Slimmer Sepracor The big-pharma company reduces its sales team after a government decision forces price cuts for one of its top drugs. Investors, take note. |
The Motley Fool
October 27, 2006
Brian Lawler |
Wake Up to Sepracor Its insomnia drug is taking hold, and sales of its other drug jumped, too. If Sepracor can slim down its marketing spending, earnings should skyrocket. Investors, take note. |
The Motley Fool
March 9, 2004
David Nierengarten |
Sepracor's No Sleeper FDA approval for its sleeping medication sends Sepracor's stock up 70%. |
The Motley Fool
September 12, 2007
Brian Orelli |
Butterflies Move Eastward Sepracor and GlaxoSmithKline ink a deal to market Lunesta worldwide. The market in Europe for sleep aids last year was about $500 million, but only about a quarter of insomnia sufferers are on medication, so there's certainly room for the market to grow. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Snoozing for Sepracor The pharmaceutical sees troubling sales trends with a key product. Investors, take note. |
The Motley Fool
July 30, 2007
Brian Orelli |
Why Sepracor Investors Can't Sleep Shares of the drug maker were hammered after the company announced lower than expected earnings and a not so bright future. |
BusinessWeek
January 17, 2005
Weintraub & Barrett |
Waking Up The Insomnia Market On Dec. 16, Sepracor Inc. won approval from the Food & Drug Administration to market Lunesta, a new sleep aid. Giddy investors pushed Sepracor's stock up 16%, to $60, in the two weeks following the news. |
The Motley Fool
October 30, 2007
Brian Orelli |
Big Pharma's Takeover Wish List Which companies may be the next big pharma buyout candidates? Investors, take note. |
The Motley Fool
December 17, 2004
Brian Gorman |
Sepracor's Dream Drug? Investors should be awake to Lunesta's potential pitfalls. |
The Motley Fool
February 17, 2005
Karl Thiel |
Sleeping on Neurocrine's Shares Why haven't Neurocrine Biosciences shares moved? It's partly history, with delays in getting an insomnia drug to market. |
BusinessWeek
June 11, 2007
Mara Der Hovanesian |
Why Seprecor May Surprise The Naysayers Sentiment is mixed on Wall Street about Sepracor, the Marlborough pharmaceutical best known for its sleep drug, Lunesta. |
The Motley Fool
September 17, 2009
Brian Orelli |
Sleepless in Sanofi It's nothing but sleepless nights for sanofi-aventis, and there's no drug to cure it. |
BusinessWeek
January 26, 2004
Arelene Weintraub |
"Exploring New Paradigms in Sleep" Two top execs from Sanofi, maker of the popular drug Ambien, talk about the challenges of staying on top in the insomnia market. |
BusinessWeek
April 23, 2007
Alex Halperin |
Vioxx Casts A Long, Long Shadow More than two years after Merck & Co. pulled its Vioxx painkiller from shelves over heart attack and stroke risks, the Food & Drug Administration is still skittish about the safety of drugs currently on the market and those coming up for review. |
The Motley Fool
October 18, 2004
Charly Travers |
Biotech's 5-Baggers How can yesterday's biotech winners lead you to today's top performers? |
The Motley Fool
August 30, 2004
Charly Travers |
It's a Hard-Knock Market You can never eliminate the risk in investing, but you can manage risk by understanding where you're putting your money. |
BusinessWeek
August 15, 2005
Barrett & Weintraub |
Drugmakers Are Changing Channels All those "Ask your doctor if it's right for you" ads on TV haven't delivered. As drugmakers labor to develop more educational and balanced pitches, they're also trying to better target their messages. |
